Literature DB >> 26370026

In postmenopausal women with breast cancer treated with aromatase inhibitors, denosumab reduced fractures.

Nicholas Wilcken, Clara Inkyung Lee.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26370026     DOI： 10.7326/ACPJC-2015-163-6-011

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN： 0003-4819            Impact factor:   25.391


× No keyword cloud information.
  2 in total

1.  Denosumab versus zoledronic acid for preventing symptomatic skeletal events in Asian postmenopausal women with oestrogen-receptor-positive advanced breast cancer: an outcome analyses with a mean follow-up of 3 years.

Authors:  Chi Zhang; Fan Zhang; Guanzhao Liang; Xianshang Zeng; Weiguang Yu; Zhidao Jiang; Jie Ma; Mingdong Zhao; Min Xiong; Keke Gui; Fenglai Yuan; Weiping Ji
Journal:  BMC Musculoskelet Disord       Date:  2018-11-30       Impact factor: 2.362

Review 2.  A Review on the Role of Denosumab in Fracture Prevention.

Authors:  Kok-Lun Pang; Nie Yen Low; Kok-Yong Chin
Journal:  Drug Des Devel Ther       Date:  2020-10-01       Impact factor: 4.162
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.